

Susvimo® (ranibizumab) - New indication

- On February 4, 2025, <u>Genentech announced</u> the FDA approval of <u>Susvimo (ranibizumab)</u>, for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor medication.
- Susvimo is also approved for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor medication.
- The approval of Susvimo for the new indication was based on a randomized, visual assessor-masked, active treatment-controlled study in 634 patients with DME. Patients were randomized to receive continuous delivery of Susvimo via the implant every 24 weeks or 0.5 mg intravitreal ranibizumab injections every 4 weeks. The primary endpoint was the change from baseline in distance Best Corrected Visual Acuity (BCVA) score averaged over week 60 and week 64.
 - Susvimo demonstrated that it was noninferior to intravitreal ranibizumab injections administered every 4 weeks. The change in BCVA scores from baseline were 9.6 and 9.4 for Susvimo and intravitreal ranibizumab, respectively (difference 0.2, 95% CI: -1.2, 1.6).
- Susvimo carries a boxed warning for **endophthalmitis**.
- The recommended dose of Susvimo for both of its indications is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the Susvimo ocular implant with refills administered every 24 weeks (approximately 6 months).
 - Supplemental treatment with 0.5 mg (0.05 mL of 10 mg/mL) intravitreal ranibizumab injection may be administered in the affected eye while the Susvimo implant is in place and if clinically necessary.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.